Drug Discovery Informatics Market Size, Share, Growth Analysis, By Workflow(Discovery Informatics and Development Informatics), By Mode(Outsourced, and In-house), By Services(Sequence Analysis Platforms, Molecular Modeling, Docking, Clinical Trial Data Management), By Region - Industry Forecast 2024-2031

Global Drug Discovery Informatics Market size was valued at USD 2.96 Billion in 2022 and is poised to grow from USD 3.29 Billion in 2023 to USD 7.76 Billion, at a CAGR of 11.30% during the forecast period (2024-2031).

The drug discovery informatics market is expected to rise in the coming years as a result of advances in high-performance computing and online services, increased usage of in-silico modeling techniques, a growing volume of drug development data, and rising demand for innovative pharmaceutical moieties. The introduction of improved drug discovery information technologies is expected to heighten industry competition. Certara, Inc., for example, released version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulation’s platform in January 2021. The new models aid in assessing and analyzing medication activity throughout pregnancy and breastfeeding.

Furthermore, it assists clients in making key decisions regarding optimizing drug safety and efficacy profiles. Companies are also growing implementing informatics technologies to reduce the lengthy drug research schedule. Curve Therapeutics Ltd., for example, will handle its biologically encoded Microcycle platform in 2021 using the CDD Vault platform. It is a widely used hosted platform for applications in pharmaceutical, biotechnology, & academic institutes for the secure and frictionless sharing of data in real-time, encouraging collaborative discoveries.

In addition, more rapid Covid-19 medication discovery around the globe is adding to market growth. For example, in order to provide quick solutions, scientists used virtual screening using drugs from the DrugBank to target viral proteins in and human ACE2 receptors. These investigations relied on silico techniques for screening small compounds with the potential to be used in drug discovery against Covid-19.

Similarly, companies are developing a variety of digital services and solutions to aid in the various stages of drug development for Covid-19. for example, the IBM visual molecular explorer platform investigated a subset of the produced compounds targeting the coronavirus (SARS-CoV-2). The explorer's open-source sharing of AI-generated artifacts aided in the early stages of optimal medication design.